Amezinium (methylsulfate)

Amezinium (methylsulfate) (CAS No.: 30578-37-1) is a synthetic small molecule classified as an indirect sympathomimetic research compound and monoamine regulatory modulator that is primarily used in cardiovascular and autonomic pharmacology studies to investigate catecholaminergic control of vascular tone and hemodynamic regulation; mechanistically, published pharmacology indicates preferential inhibition of intraneuronal monoamine oxidase A activity together with suppression of neuronal noradrenaline reuptake and reduced tyramine uptake, accompanied by functional stimulation of alpha and beta 1 adrenergic signaling and weaker alpha 2 antagonistic effects at higher exposure, thereby supporting its use as a systems level probe of sympathetic neurotransmission, presynaptic catecholamine handling, and receptor coupled vasopressor responses in preclinical settings; reported enzyme inhibition potency is described at low micromolar levels for MAO A, and broader activity in experimental platforms is generally characterized within micromolar concentration ranges depending on assay format, species, and endpoint selection; in vitro, it is commonly applied in assays of monoamine metabolism, transporter associated catecholamine dynamics, and adrenergic response profiling, while in vivo it is used in animal models of blood pressure regulation and circulatory reflex function where changes in plasma noradrenaline, vascular resistance, and heart rate related parameters can be monitored as research readouts; in drug discovery workflows, this agent is relevant as a reference modulator for screening compounds that affect sympathetic nerve terminal biology, adrenergic receptor linked pathways, or neurohumoral cardiovascular homeostasis, and the concentrations or doses used in experiments typically depend on specific experimental designs and research objectives.